Member Info for BuenaVista

One more sleep after the England game.

Who said they would provide the service for all hires? Sounded to me like an additional option when available and if not, client would be offered hydrogen from another provider.

Well, the rest of the form?😂😂😂

Has the whole form been put in detention?

Now is the time for AFC and the other good hydrogen companies. Do you really think there was a viable business years ago when the technology wasn't optimised, there was no infrastructure and there was no need, desire or financial backing to move away from traditional forms of energy?

...to FAP-rich environments. I'd be very interested to know whether Avacta is talking with pharma companies about licensing the platform out for other diseases.

"Last year [2017], companies outside the top 10 grabbed just 21.5% of the market. That number is set to nearly double by 2024—swelling to 39.7%—thanks to big recent approvals for companies including Gilead Sciences, Eli Lilly, Tesaro, Clovis and more."

Wiki - https://en.wikipedia.org/wiki/Tesaro - says: "Tesaro was founded in 2010.[1] The company's first commercial product, Varubi, was approved by the FDA in October 2015.[2] As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD.[3] The company's product Niraparib was granted priority review and was given a target action date of June 2017 by the FDA.[4] In March 2017, Tesaro won approval for its drug Zejula to treat ovarian cancer.[5] On May 31, 2017, it was reported that Tesaro Inc. was exploring a sale.[5] On December 3, 2018, GSK announced it would acquire the company for $5.1 billion,[6] and the deal was completed on January 22, 2019.[7]"

On that scale, Avacta shares would be 1444p but Avacta is in a far stronger position to license and fund future growth.

Great article ES. Thanks for posting. pre|CISION and Affimers would have slotted right into that article, if the author were aware of them. Working platforms are definitely the way to go for investing and Avacta's are right up there.

And anyway, as I wrote last week before buying my hat, there's been a terrible mix-up with the units and it'll all have to be done again, so how can the FDA make a decision if they've not been given the data?

Not just via RNS, also to the TG peeps a month later, on 18 October.

I've no doubt it will happen. Why else would he put his reputation on the line like that? Sujood that is.😉

Sorry to hear cancer has affected your nearest and dearest so severely.

Agree what you say about the extent of the impact of pre|CISION. Since reading the summary and contents of a market report, I've wondered whether the 'Doxorubicin market' includes all the anciliary hard costs such as drugs for side effects.

Or Truant. that 'bio' did sound very familiar.

OK, so just the number of contacts, not who they are.

Well I got that rather wrong!

I see the original owner and one tweet (a repost) in Google cache, but where did you get the rest of the information about what the account contained, especially the contacts, before it was changed?

https://webcache.googleusercontent.com/search?q=cache:9lXM5cluMncJ:https://twitter.com/Capitelize

As your pronouncements are usually so painfully off target, I am now beginning to think yes, it is Ripley.

Not fully awake yet. I meant 'when given an LSE detention, uses that Twitter account for the first time to post his grievances'

Yes, it seems very odd. To create the Twitter account in February, join LSE in October, stir up as much hatred and anger as he can and then, and only then, when given an LSE detention, to post his grievances (poor victim that he is) on Twitter. He does seem a very odd person.

😂😂😂

Very interesting. And stupid.

Good spot 13th!

So now we know potty mouthed NYsize is a follower of TW and his sole purpose here was to cause disruption. Well, he'll now be unfiltered and every disruptive post will be reported. Narcissist - 🤣🤣🤣

RNS of 19 September (Successful Completion of Sixth Dose Escalation): "The Company expects to publish detailed data from the ALS-6000-101 clinical study, including clinical and pharmacokinetic data, in the fourth quarter of 2023."

AS to TG on 18 October: "...we intend to present the full pharmacokinetic and clinical data later in Q4 including case studies if that is permitted."

Is an "intend" better than an "expect" better than an "aim"?

Also, if the fortnightly study is to run "in parallel" with C7, the FDA better get a move on or the patients in C7 will need to go slower. It'll be 9 (NINE) weeks / 63 (SIXTY-THREE) days on Tuesday 21 November, the AVAGO day.

It just beggars belief that we can be this close to several major announcements yet the share price keeps taking on water.

Anyway CJ, enjoy your exercise and replenishing your liquid level.